# A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

> **NCT05021120** · EARLY_PHASE1 · COMPLETED · sponsor: **Akesobio Australia Pty Ltd** · enrollment: 67 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumours

## Interventions

- **DRUG:** AK127
- **DRUG:** AK104

## Key facts

- **NCT ID:** NCT05021120
- **Lead sponsor:** Akesobio Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-12
- **Primary completion:** 2024-10-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05021120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05021120, "A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05021120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*